口腔颌面部鳞癌组织中p16基因变异的初步研究  

Genetic Alteration of p16Gene in Oral and Maxillofacial Squamous Cell Carcinomas

作　　者：刘德胜[1] 鲁中好[1] 张传泽[1] 

机构地区：[1]山东省日照市人民医院口腔科,山东日照276800

出　　处：《上海口腔医学》2002年第3期226-228,共3页Shanghai Journal of Stomatology

摘　　要：目的检测口腔颌面部鳞癌中p16基因的缺失和突变,以了解p16基因在口腔颌面部恶性肿瘤发生发展过程中的作用。方法应用聚合酶链反应-单链构象多态性分析(PCR—SSCP)技术,检测33例原发性口腔颌面部鳞癌的石蜡标本,将p16基因的变异频率与口腔颌面部鳞癌的临床分期、组织学分级及淋巴结转移进行统计学分析。结果p16基因的缺失率为21%,点突变率为6%,变异频率为27%。临床I、II、III、IV期每两期之间无显著性差异(P>0.05);而临床I、II期和III、IV期之间有显著性差异(P<0.05)。组织学分级和有、无淋巴结转移之间p16基因变异无显著性差异(P>0.05)。结论p16基因的缺失和突变是口腔颌面部鳞癌中常见的分子事件,它的失活在口腔颌面部鳞癌的发生发展中起着重要作用;说明其变异与肿瘤的临床分期密切相关,随着肿瘤临床进程的发展,其变异频率增高。研究未发现其变异与肿瘤组织学分级和淋巴结转移之间存在相关关系。Objective To detect p16gene alteration in oral and maxillofacial squamous cell carcinomas(OMSCC)and its relation with this tumor type.Methods To examine33paraffin-embedded cases of primary oral and maxillofacial squamous cell carcinoma by PCR-SSCP method and analysize relationship of p16gene alteration with clinical stages,histological grades,lymphatic metastasis in OMSCC.Results It revealed9of33(27%)with p16gene change including7(21%)homozyguos deletions and2(6%)point mutations.There were no significant differences among clinical stage I-IVeach other(P>0.05),but there were significant differences between clinical stage I+II and clinical stage III+IV(P<0.05);P16gene alteration did not significantly differ among histological grading,lymphatic metastasis positive group and negative group in OMSCC.Conclusions Genetic deletion and mutation of p16gene are frequent molecular events in this kind of tumor,its inactivation has played a important role in the developmental course of OMSCC.p16gene alteration closely correlates with clinical stages,and the frequency of its alteration may increase following the development of tumor clinical course.The results can be used to evaluate the prognosis and assist in diagnosis of the patients.But no relation with histological grades and lymphatic metastasis which still remains to further study.

关 键 词：口腔颌面部鳞癌 P16基因 缺失 点突变 复合酶链反应 PCR-SSCP 

分 类 号：R739.8[医药卫生—肿瘤]